BridgeBio Pharma Inc
$ 74.15
3.76%
03 Dec - close price
- Market Cap 14,289,359,000 USD
- Current Price $ 74.15
- High / Low $ 74.34 / 71.16
- Stock P/E N/A
- Book Value -10.04
- EPS -4.21
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.44 %
- ROE -17.90 %
- 52 Week High 74.34
- 52 Week Low 25.34
About
BridgeBio Pharma, Inc. is a leading biopharmaceutical company based in Palo Alto, California, focusing on the discovery, development, and commercialization of innovative therapies for genetic diseases and rare disorders. With a robust pipeline and a commitment to addressing critical unmet medical needs, BridgeBio employs advanced scientific methodologies to create transformative treatments. The company’s dedication to improving patient outcomes positions it as a formidable player in the genetic medicine space, with a vision to redefine care standards for underserved patient populations.
Analyst Target Price
$84.65
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-08-05 | 2025-04-30 | 2025-02-20 | 2024-11-01 | 2024-08-01 | 2024-05-02 | 2024-02-22 | 2023-11-02 | 2023-08-03 | 2023-05-04 | 2023-02-23 |
| Reported EPS | -0.7166 | -0.95 | -0.9888 | -1.3744 | -0.8596 | -0.39 | -0.2 | -0.96 | -1.08 | -0.98 | -0.92 | -0.92 |
| Estimated EPS | -0.8577 | -0.75 | -0.89 | -1.09 | -0.98 | -1.06 | -0.71 | -0.91 | -0.82 | -0.83 | -0.83 | -0.85 |
| Surprise | 0.1411 | -0.2 | -0.0988 | -0.2844 | 0.1204 | 0.67 | 0.51 | -0.05 | -0.26 | -0.15 | -0.09 | -0.07 |
| Surprise Percentage | 16.451% | -26.6667% | -11.1011% | -26.0917% | 12.2857% | 63.2075% | 71.831% | -5.4945% | -31.7073% | -18.0723% | -10.8434% | -8.2353% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BBIO
2025-10-25 06:32:40
BridgeBio (NASDAQ: BBIO) has announced two upcoming investor events: a webinar on Monday, October 27, 2025, at 8:00 AM ET, to present interim topline Phase 3 results from the LGMD2I/R9 FORTIFY study, and its Q3 2025 earnings call on Wednesday, October 29, 2025, at 4:30 PM ET. Management will host both events, with webcasts accessible via the company’s investor relations page. Replays will be available for 90 days following each event.
2025-10-25 06:32:40
BridgeBio Pharma, Inc. (BBIO) maintains its $68 price target due to strong launch dynamics for its products, particularly the successful German launch of Beyonttra (Attruby). The company's management anticipates third-quarter performance to be similar to the second quarter, buoyed by wide access post-approval. BridgeBio has demonstrated significant one-year and three-year returns of 100.67% and 413.98% respectively, outperforming the market.
2025-10-25 06:32:40
BridgeBio Pharma, Inc. announced upcoming business update calls for next week. These calls will include the Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) FORTIFY Phase 3 Interim Analysis Topline Results Webinar and the Third Quarter 2025 Earnings call. Investors and interested parties can access the live webcasts via the company's investor relations website.
2025-10-15 08:08:37
Vontobel Holding Ltd. has acquired a new position of 9,830 shares in BridgeBio Pharma, Inc. (BBIO), valued at approximately $424,000. Other institutional investors also adjusted their holdings in BridgeBio Pharma, with KLP Kapitalforvaltning AS and Platinum Investment Management Ltd. increasing their stakes, among others. Analysts from Scotiabank and Bank of America have recently updated their target prices for BridgeBio Pharma, both maintaining "buy" or "sector outperform" ratings.
2025-10-14 18:04:28
BridgeBio Pharma, Inc. reached a new 52-week high of $56.24 on October 13, 2025, marking a 101.08% increase over the past year, significantly outperforming the S&P 500. Despite strong financial metrics like a 42.43% return on equity and a market capitalization of $10,715 million, the company is currently loss-making with unique financial ratios. Markets Mojo provides an overall stock analysis highlighting weak long-term fundamentals, negative results, high risk, and reducing promoter confidence.
2025-10-14 13:50:28
The article reports that BridgeBio Pharma stock reached a new 52-week high of $56.28 USD. However, due to a client-side exception, the full content of the Investing.com article regarding this event is currently unavailable.
